Filing Flows › Orchestra BioMed Holdings (OBIO) › Q2 2026
Orchestra BioMed Holdings (OBIO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 10, 2026
Orchestra BioMed Holdings (OBIO) reported revenue of $88K for the second quarter 2026 (Q2 2026), -89% from a year earlier and -20% from the quarter before.
Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year), net loss $23.8M, operating cash flow −$19.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $88K | -20% | -89% |
| Operating profit | −$22.4M | — | — |
| Net earnings | −$23.8M | — | — |
| Operating cash flow | −$19.3M | — | — |
What changed
Revenue was $88K in Q2 2026, down 89% year over year and down 20% from the previous quarter.
Operating costs exceeded revenue by $22.4M, an operating margin of -25404.5%. Total costs grew 11% against a revenue fall of 89%. The fastest-growing cost line was Research & development (+20%). The quarter ended with a net loss of $23.8M, wider than the previous quarter's $20.7M loss.
Operating cash flow was −$19.3M. Non-cash charges added back $96K of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items added $1.8M. Capital expenditures of $254K exceeded it, leaving free cash flow of −$19.6M.
Questions
What was Orchestra BioMed Holdings' revenue in the second quarter 2026?
Orchestra BioMed Holdings (OBIO) reported revenue of $88K for the second quarter 2026 (Q2 2026), -89% from a year earlier and -20% from the quarter before.